Skip to main content
×
Home
About Us
Company Summary
Senior Management
The Board
Corporate Governance
Board Charter
Audit & Risk
Remuneration & Nominations
Code of Conduct
Continuous Disclosure
Risk Management
Shareholder Communication
Securities Trading
Board & Executive Evaluation
Diversity
Therapeutic Areas
Technology
MSCs
Immunotherapy
Sygenus
Product Pipeline
Pipeline Overview
Human Health
Progenza
Human Cancer Vaccine
Sygenus
Animal Health
CryoShot Canine
Kvax
Trials
Investors
ASX announcements
Financials
Analyst Coverage
Events & Presentations
Investor Relations Contact
Subscribe
News
2019
2018
2017
2016
2015
2014
2013
Contact
Home
About Us
Company Summary
Senior Management
The Board
Corporate Governance
Therapeutic Areas
Technology
MSCs
Immunotherapy
Sygenus
Product Pipeline
Pipeline Overview
Human Health
Animal Health
Trials
Investors
ASX announcements
Financials
Analyst Coverage
Events & Presentations
Investor Relations Contact
Subscribe
News
2019
2018
2017
2016
2015
2014
2013
Contact
Home
Investors
ASX announcements
2013
ASX announcements
2020
2019
2018
2017
2016
2015
2014
2013
Date
Title
27/11/2013
Address by Regeneus Executive Chairman John Martin to 2013 Annual General Meeting
27/11/2013
Results of RGS AGM
25/11/2013
Regeneus to fast-track human cells under new Japanese laws
20/11/2013
BBY Life Sciences Conference - RGS Presentation
14/11/2013
Novel canine cancer vaccine gets green light for commercialisation in USA
30/10/2013
HiQCell stem cell therapy now available in Melbourne
29/10/2013
ASX Spotlight Asia Conference - Presentation by Duncan Thomson, Head of Animal Health
24/10/2013
Notice of Annual General Meeting
24/10/2013
RGS Shareholder Proxy Form
08/10/2013
Positive Biomarker Results in World-First Stem Cell Knee Osteoarthritis Trial